Partnerships

Nanomedical Diagnostics collaborates with world-renowned research and manufacturing institutions to develop Field Effect Biosensing (FEB) technology into applications for life science research, drug discovery, and portable diagnostic and health monitoring.

 

cdc partnership with Nanomedical Diagnostics

The CDC is evaluating FEB technology for disease diagnostic systems.

Mayo Clinic partnership with Nanomedical Diagnostics

Mayo Clinic is evaluating the diagnostic capabilities of FEB technology.

Stanford partnership with Nanomedical Diagnostics

Stanford utilizes Agile R100 to gather in vitro kinetic binding data for peer-reviewed publications, including Nature.

Scripps Research Institute logo

The Scripps Research Institute uses Agile R100 in their drug discovery program.

Hamilton Robotics partnership with Nanomedical Diagnostics

Nanomed is partnering with Hamilton Robotics to ensure Agile R200 integrates seamlessly with Hamilton products.

Abilita bio

Abilita is using Agile R100 to characterize mutated GPCRs.

Navy logo partnership with Nanomedical Diagnostics

Base Pair Biotechnologies is using Agile R100 functionalized with aptamers to detect small molecules for pharmacokinetic studies.

Keck Graduate Institute KGI partnership with Nanomedical Diagnostics

KGI is using FEB technology to develop point-of-care applications with no sample processing for genetic diseases.

Johns Hopkins partnership with Nanomedical Diagnostics

Johns Hopkins is evaluating FEB technology to use in hand-held drug detection devices.

Rogue Valley Microdevices partnership with Nanomedical Diagnostics

RGM is a co-developer of the only commercial graphene biosensor fabrication process in the world.

samtec partnership with Nanomedical Diagnostics

Samtec is our packager of large-scale quantities of graphene biosensor chips.

Evonexus logo

Nanomedical Diagnostics was one of nine companies accepted out of 104 applicants for this top San Diego start-up incubator.